Pressemitteilungen
BioVentrix® Closes $48.5 Million Series A Financing
Financing led by Andera Partners including Cormorant Asset Management, Taglich Brothers Inc., Squarepoint Capital, and Richmond Brothers to Support Premarket Approval of Revivent TC® System for Patients with Ischemic Heart Failure MANSFIELD, MA – April 13, 2023 – BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies to directly treat the [...]
New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy
Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device Therapy MANSFIELD, MA, USA – March 15, 2023 – BioVentrix®, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle leading to progressive heart failure, today announced the publication of a peer-reviewed paper in the Journal [...]
BioVentrix Names Dr. Ori Ben-Yehuda as Chief Medical Officer
Brings Extensive Clinical Trial and Patient Care Experience to Senior Management Team SAN RAMON, Calif. – February 08, 2023 – BioVentrix, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart failure, [...]
FDA Agrees to Expanded Access Program for the BioVentrix Revivent TC® System for the Treatment of Ischemic Heart Failure
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif. – January 24, 2023 – BioVentrix, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart failure, [...]
BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.
Revolutionary Heart Failure Therapy Company Also Adds New Executive and Well-Known Board Member to Enhance Expertise SAN RAMON, Calif. – January 27, 2022 - BioVentrix, Inc., a privately held medical device company focused on less invasive therapies to treat the left ventricle (LV), known to be the root cause of congestive heart [...]
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors
SAN RAMON, Calif. – July 21, 2021 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company’s chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors.Mr. Cohen [...]
BioVentrix Names Jim Dillon President and CEO
Proven Leader Will Take Revolutionary Heart Failure Therapy Company to Next LevelSAN RAMON, Calif. - April 29, 2021. BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter-based Ventricular Restoration (TCVR), today announced that Jim Dillon has been named President and CEO.In his role, Mr. Dillon will [...]
Kardio-Tech-Firma aus Kalifornien gründet Deutschland-Niederlassung und macht so innovative Herztherapie breiter verfügbar
San Ramon, Kalifornien, und Hilden bei Düsseldorf, 19. Februar 2021„Bringing innovation in cardiology from California to Germany.“ So könnte die Überschrift einer der jüngsten Firmengründungen in der Medizintechnik-Branche in Deutschland lauten. BioVentrix Inc. ist ein in Privatbesitzt befindliches Unternehmen mit Hauptsitz im kalifornischen San Ramon (USA). Die Firma wurde 2007 gegründet und ist auf [...]
BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System
SAN RAMON, Calif. – February 8, 2021 - BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter [...]
BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure
SAN RAMON, Calif. – January 6, 2021 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE Therapy [...]
BioVentrix Announces the Appointment of Cardiac Device Veteran Chris Wolff as Vice President of U.S. Sales
San Ramon, CA, USA – October 5, 2020 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that Chris Wolff has been named Vice President of U.S. Sales. In this role, Mr. Wolff will be responsible for driving enrollment in [...]
Neuartige Herzoperation in Tübingen durchgeführt
Das Tübinger Herzzentrum hat nach einer Corona-bedingten Zwangspause erfolgreich einen Herzschwäche-Patienten mit einem neuartigen Verfahren behandelt. Dabei wurde die linke Herzkammer verkleinert. Der 60-Jährige wurde nach einem Herzinfarkt immer schwächer. Zuletzt konnte er nur noch wenige Schritte ohne Pause gehen.Nach der Operation mit der minimalinvasiven Methode gehe es dem Patienten nun wesentlich besser, heißt [...]
Kasuistik zur Postinfarkt-Herzinsuffizienz publiziert
January 27, 2022 Erfolgreiches minimalinvasives Postmyokardinfarkt-Verfahren führt zu einem Anstieg der linksventrikulären Ejektionsfraktion von 20 auf 35%Patienten nach Myokardinfarkt entwickeln trotz leitliniengerechter Herzinsuffizienz-Therapien (GDMT, guideline-directed medical therapy) oft fortschreitende Herzinsuffizienz-Symptome.Nun wurde im European Heart Journal eine Kasuistik publiziert, in der ein Patient mit Postinfarkt-Herzinsuffizienz mit dem Revivent TC™-System behandelt wurde.1Dabei wurde mittels minimalinvasiv eingebrachter [...]
BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause
San Ramon, Calif. – September 2, 2020 – BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE™ Therapy, using the Revivent TC™ Transcatheter Ventricular Enhancement System.The [...]
BioVentrix Announces Appointment of Accredited Public Company Director, Raymond W. Cohen, to its Board of Directors
SAN RAMON, Calif. – August 12, 2020 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company’s board of directors.Mr. Cohen, an accredited public company director, has nearly 40 years of experience leading [...]
Innovatives kathetergestütztes Verfahren, LIVE“ zur Behandlung der Herzschwäche nach Herzinfarkt
Erstmals in Deutschland vorgestelltDie anhaltende infarktbedingte Herzschwäche besitzt weltweit eine hohe klinische Bedeutung, typisch sind eine erhöhte Sterblichkeitsrate und wiederkehrende stationäre Krankenhausaufent-halte.Patienten nach einem Herzinfarkt entwickeln trotz leitliniengerechter Herzschwäche-Therapien oft fortschreitende Herzschwäche-Symptome, die auch auf einer Narbenbildung am Herzmuskel be-ruhen können.Die Prognose dieser Erkrankung ist ungünstig: Ca. 50 % der Patienten mit der Diagnose [...]
FierceMedTech Names BioVentrix as One of Its “Fierce 15” Companies of 2019
SAN RAMON, Calif. — March 9, 2020 — BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that it has been named by FierceMedTech as one of the “Fierce 15” for 2019, designating it as one of the most promising private medtech companies in [...]
Dr. Ralph Stephan von Bardeleben als Co-Principal Investigator für die randomisierte klinische Studie REVIVE-HF von BioVentrix bekanntgegeben
San Ramon, Kalifornien – 4. März 2020 – BioVentrix, Inc., Hersteller des ersten katheter-basierten Systems zum linksventrikulären Remodeling nach Herzinfarkt, hat heute bekannt-gegeben, dass Dr. med. Ralph Stephan von Bardeleben vom Universitätsklinikum Mainz als Co-Principal Investigator bei der in Europa durchgeführten klinischen Studie REVIVE-HF zur Less Invasive Ventricular Enhancement (LIVETM)-Therapie mit dem Revivent TCTM-System [...]
BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial
REVIVE-HF seeks to demonstrate superiority of the Revivent TC System to current guideline treatment for heart failureSAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the [...]
BioVentrix Announces Gregg Stone, MD, as Co-Principal Investigator for ALIVE Pivotal Trial of Transcatheter Device for Heart Failure
SAN RAMON, Calif. – February 18, 2020 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New York’s Mount Sinai Health System has signed on to the pivotal ALIVE Trial of the Revivent TC™ TransCatheter Ventricular Enhancement System [...]
Innovative Herzinfarkttherapie: Angebot in Deutschland wächst
Für Herzinfarkt-Patienten ist die innovative LIVE™-Therapie (Less Invasive Ventricular Enhancement) schonender als eine herkömmliche Operation, und sie verbessert nachweislich sowohl die Herzleistung als auch die Lebensqualität der Betroffenen.Die Zahl der Zentren, die dieses Verfahren anbieten, nimmt stetig zu. Jüngstes Beispiel ist das Asklepios Klinikum Harburg, das kürzlich die LIVE™-Therapie erfolgreich eingeführt hat.Hamburg, 17. Februar [...]
BioVentrix Receives 2020 NUB Reimbursement Status 1 Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System
San Ramon, CA – February 6, 2020 – Bioventrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the highest priority reimbursement in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System by achieving the NUB Status 1 designation from InEk, the [...]
Europäische Kommission verlängert die CE-Zulassung für das BioVentrix Revivent TC System der LIVETM Therapie (Less Invasive Ventricular Enhancement)
San Ramon, Kalifornien – 22. Januar 2020 – BioVentrix, Inc., Hersteller des ersten transkatheter-basierten Systems zum linksventrikulären Remodeling nach Herzinfarkt, hat heute die Verlängerung der CE-Zulassung für das Revivent TCTM Transcatheter Ventricular Enhancement System zur Be-handlung von Herzinsuffizienz bis Mai 2024 bekannt gegeben.„Die Verlängerung der CE Zulassung ist nicht nur ein wichtiger Meilenstein für [...]
European Commission Grants BioVentrix CE Mark Extension for Revivent TC Less Invasive Ventricular Enhancement Therapy
SAN RAMON, Calif. – January 22, 2020 – BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced the extension of its CE Mark for the Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure to May 2024."The extension of our CE Mark is not only [...]
BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System
Study Published in European Journal of Heart Failure Shows Significant and Sustained Improvement in Heart Function, Symptom Relief and Quality of Life Using Less Invasive Left Ventricular Enhancement DeviceSan Ramon, CA – Dec. 04, 2019 – Bioventrix, Inc., developer of the first less invasive system for left ventricular remodeling, today announced online publication of [...]
